In:
Journal of Medical Virology, Wiley, Vol. 93, No. 1 ( 2021-01), p. 223-233
Abstract:
SARS‐CoV‐2 hematological patients are at a high risk to develop severe clinical events and die. In oncohematologic diseases involving T lymphocytes, NK, histiocytes, and antigen‐presenting cells, there is a risk of an immunological hyperactivation induced by SARS‐CoV‐2. In patients with aplasia, bone marrow hypoplasia, neoplastic invasion of bone marrow, and in those with neutropenia, SARS‐CoV‐2 free to replicate and spread into the body causes a direct strong cell damage. SARS‐CoV‐2 exerts pathogenetic action in hematological patients, in patients treated with immunosuppressive therapy, or immunochemotherapy, in those who underwent bone marrow transplantation and in those with indolent chronic hematological diseases such as hemolytic anemia, autoimmune thrombocytopenia, and aplastic anemia. The current strategy to treat COVID‐CoV‐2 patients includes antivirals used against other viral infections, drugs active in moderating the cytokine storm and anticoagulants.
Type of Medium:
Online Resource
ISSN:
0146-6615
,
1096-9071
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
752392-0
detail.hit.zdb_id:
1475090-9